Skip to main content
About the Institute
  • English
  • Français
  • Español
  • Russian

Breadcrumb

  1. Home
  2. Functional gastrointestinal disorders from childhood to adulthood
  3. Modulation of the microbiota by FMT: controversial results
  • Our publications
    • News
    • Microbiota Mag
    • Thematic pages
    • Experts' point of view
    • Thematic folders
    • Overviews - Microbiota Magazine
  • About the Institute
    • Partnerships
    • Press room
    • International Microbiota Observatory
  • Congresses
    • Congress calendar
    • Congress reviews
  • Continuing Medical Education
    • Accrediting courses
    • Xpeer App
  • Useful documents
    • Infographics
    • IBS Diagnosis Check List
    • Patients Stories
    About the Institute

    Join the microbiota community

    • Facebook
    • Twitter
    • LinkedIn
    • YouTube

Lay public section

Find here your dedicated section
Gastroenterology
Gynecology
Pediatrics
Dermatology

Breadcrumb

  1. Home
  2. Functional gastrointestinal disorders from childhood to adulthood
  3. Modulation of the microbiota by FMT: controversial results
Gastroenterology

Modulation of the microbiota by FMT: controversial results

Functional gastrointestinal disorders
Pediatrics Gastroenterology

Fecal transplant, targeted diets, probiotic supplementation...: although the prospects are promising, the conclusions of some publications point not only to the complexity of the subject but also to its limitations.16,17

Gastroenterology
Gynecology
Pediatrics
Dermatology
  • Our publications
    • News
    • Microbiota Mag
    • Thematic pages
    • Experts' point of view
    • Thematic folders
    • Overviews - Microbiota Magazine
  • About the Institute
    • Partnerships
    • Press room
    • International Microbiota Observatory
  • Congresses
    • Congress calendar
    • Congress reviews
  • Continuing Medical Education
    • Accrediting courses
    • Xpeer App
  • Useful documents
    • Infographics
    • IBS Diagnosis Check List
    • Patients Stories
    About the Institute

    Join the microbiota community

    • Facebook
    • Twitter
    • LinkedIn
    • YouTube

Lay public section

Find here your dedicated section

Sources

This article is based on scientific information

Sharing is caring

Your colleagues might be interested in this topic. Why not share it?

  • Facebook
  • Twitter
  • LinkedIn
  • Mail

Sections

About this article

Created 15 October 2019
Updated 06 January 2022

The efficacy of fecal transplant in the treatment of dysbiosis seems proven, but its impact on FGIDs is more questionable.

REAL EFFICACY AGAINST DYSBIOSIS

A Danish study conducted in 2016 highlighted the efficacy of fecal transplant in cases of dysbiosis in IBS patients and revealed a significant improvement in the diversity of their gastrointestinal microbiota. The collection of fecal samples at each visit (enrolment, 1, 3 and 6 months) allowed the characterization of bacterial populations by sequencing. Analysis of the microbiota of the transplanted patients at 3 months revealed the presence of 11 species of interest. Two species displayed weak negative correlations with the IBS-SSS–or Irritable Bowel Syndrome Severity Scoring System–(both belonging to the Blautia genus which is associated with a healthy gastrointestinal microbiome) and three moderately positive (two belonging to the Bacteroides genus and one to the Ruminoccocaceae family). As of now, fecal transplant therefore appears to represent a technique for the treatment of dysbiosis in IBS patients, and potentially all FGIDs, although larger scale studies are required to define its clinical efficacy.

DIVERGENT RESULTS

The question is however raised: is fecal transplant also able to correct the pathological phenomena associated with dysbiosis? It is difficult to give a final answer regarding FGIDs, mainly because of the scarce number of randomized clinical studies. The few trials available in the scientific literature deal with IBS and do not yet allow a judgment to be made because of divergent conclusions.

IBS-SSS SCORE

Functioning

The IBS-SSS score is comprised of 5 parameters quantified on a 100-point analog scale.

The five items added together give a severity score between 0 and 500.

  • 0-75 > control or patient in remission
  • 75-175 > benign form
  • 175-300 > moderate
  • 300 and over > severe 

 

Criteria

  • Severity of abdominal pain;
  • Frequency of abdominal pain;
  • Severity of bloating;
  • Relief after defecation;
  • Interference with quality of life

PROS AND CONS

In Norway in 2015, 83 participants aged between 18 and 75 took part in a study: after an enema 2/3 of them received a fecal transplant and 1/3 a placebo (their own feces) in both cases via the colon. The reduction of symptoms at three months was evaluated using the IBS-SSS score. The difference was significantly in favor of transplant: 65% improvement against 43% for the placebo–a difference which was not confirmed at 12 months. The “loss of efficacy” could be explained by a powerful effect of the transplanted microbiota right after the administration, but a difficulty in grafting durably in its host due to the effect of exogenous and/ or endogenous factors. One year later in 2016, another study disproved the benefit of fecal transplant: after an enema, 52 patients with moderate or severe disease received a graft (orally) from healthy donors (n=26) or a placebo (n=26). The IBS-SSS score and quality of life were then evaluated. At 3 months, a significantly greater improvement in symptoms and quality of life was observed… in the placebo arm. Suggested hypotheses: the fecal transplant could counteract a positive effect of the enema; some pathogenic microorganisms could be removed by the enema then reintroduced by transplant; the duration of treatment or the quantity of re-implanted fecal bacteria might be insufficient.

Sources

16 Halkjær SI, Christensen AH, Lo BZS, et al. Faecal microbiota transplantation alters gut microbiota in patients with irritable bowel syndrome: results from a randomised, double-blind placebo-controlled study. Gut. 2018;67(12):2107-2115.

17 Johnsen PH, Hilpüsch F, Cavanagh JP, et al. Faecal microbiota transplantation versus placebo for moderate-to-severe irritable bowel syndrome: a double-blind, randomised, placebo-controlled, parallel-group, single-centre trial. Lancet Gastroenterol Hepatol. 2018;3(1):17-24.

Old sources

 

 

Tags
IBS Dysbiosis Gut health Functional gastrointestinal disorders

en_view en_sources

    Focus
    Functional gastrointestinal disorders from childhood to adulthood
    • Pathophysiology
      • Functional gastrointestinal disorders: a set of diseases defined in correlation with the intestinal microbiota
      • Focus on the gut-brain axis
    • FGIDS: from infants to adults
      • In newborns
      • In children and adolescents
      • In adults
    • What could be the role of microbiota modulation?
      • Modulation of the microbiota by FMT: controversial results
      • FODMAP-free diet: not for all patients
      • Probiotics: what are the benefits?
    • Expert opinion
      • Dr. Marc Bellaiche: Managing FGIDs in children
    Created 15 October 2019
    Updated 06 January 2022

    About this article

    To know more about this topic.

    Main topic

    Functional gastrointestinal disorders

    Medical practice

    Pediatrics Gastroenterology

    Content type

    Dossier detail
    In adults
    FODMAP-free diet: not for all patients
    Focus

    Functional gastrointestinal disorders from childhood to adulthood

    Pathophysiology

    Functional gastrointestinal disorders: a set of diseases defined in correlation with the intestinal microbiota Focus on the gut-brain axis

    FGIDS: from infants to adults

    In newborns In children and adolescents In adults

    What could be the role of microbiota modulation?

    Modulation of the microbiota by FMT: controversial results FODMAP-free diet: not for all patients Probiotics: what are the benefits?

    Expert opinion

    Dr. Marc Bellaiche: Managing FGIDs in children

    Continue reading

    News
    L’axe intestin-cerveau dans le stress lié à la discrimination
    20.03.2023

    The gut-brain axis and discrimination-related stress

    Read the article
    21.09.2023

    The mucin-microbiota pair - central to the development of gastric cancer?

    Read the article
    25.10.2022

    Antibiotics: Dr Jekyll and Mr Hyde

    Read the article
    13.09.2023

    Parkinson’s disease: Desulfovibrio bacteria have been found guilty

    Read the article
    02.03.2021

    Cervicovaginal microbiota: a marker for persistent papillomavirus infection?

    Read the article
    18.11.2020

    Gut microbiota signature for cirrhosis

    Read the article
    29.08.2023

    Massive amounts of antibiotic resistance genes found in clouds

    Read the article

    Gut Microbiota #18

    By Pr. Satu PekkalaAcademy of Finland Research Fellow, Faculty of Sport and Health Sciences, University of ...

    Find out more
    What's worth reading about microbiota
    Follow us on Twitter
    Read our thematic folder
    The Janus face of Antibiotics: Life Savers & Microbiota Disrupters
    Microbiota 17 EN
    Check out our latest magazine
    The first 1000 days of life
    • Our publications
      • News
      • Microbiota Mag
      • Thematic pages
      • Experts' point of view
      • Thematic folders
      • Overviews - Microbiota Magazine
    • About the Institute
      • Partnerships
      • Press room
      • International Microbiota Observatory
    • Congresses
      • Congress calendar
      • Congress reviews
    • Continuing Medical Education
      • Accrediting courses
      • Xpeer App
    • Useful documents
      • Infographics
      • IBS Diagnosis Check List
      • Patients Stories
      About the Institute

      Join the microbiota community

      • Facebook
      • Twitter
      • LinkedIn
      • YouTube

    Lay public section

    Find here your dedicated section
    Gastroenterology
    Gynecology
    Pediatrics
    Dermatology
    • English
    • Français
    • Español
    • Russian

    Browse the site

    • Our publications
      • News
      • Microbiota Mag
      • Thematic pages
      • Experts' point of view
      • Thematic folders
      • Overviews - Microbiota Magazine
    • About the Institute
      • Partnerships
      • Press room
      • International Microbiota Observatory
    • Congresses
      • Congress calendar
      • Congress reviews
    • Continuing Medical Education
      • Accrediting courses
      • Xpeer App
    • Useful documents
      • Infographics
      • IBS Diagnosis Check List
      • Patients Stories
      About the Institute

      Join the microbiota community

      • Facebook
      • Twitter
      • LinkedIn
      • YouTube

    Lay public section

    Find here your dedicated section

    Discover

    Gastroenterology
    Gynecology
    Pediatrics
    Dermatology

    Join the microbiota community

    • Facebook
    • Twitter
    • LinkedIn
    • YouTube

    Lay public section

    Find here your dedicated section

    Redirection

    You are about to be redirected and leave our website

    • Be redirected
    • Stay on the Biocodex Microbiota Institute's website

    Stay with us !

    Join the Microbiota Community of HCPs and researchers and receive “Microbiota Digest” and "Microbiota Mag" to stay up to date on the latest news about microbiota.

    * Mandatory Fields

    BMI 20-35

    Explore

    21.09.2023

    The mucin-microbiota pair - central to the development of gastric cancer?

    Read the article
    13.09.2023

    Parkinson’s disease: Desulfovibrio bacteria have been found guilty

    Read the article
    29.08.2023

    Massive amounts of antibiotic resistance genes found in clouds

    Read the article

    Stay updated

    Join the Microbiota Community of HCPs and researchers and receive “Microbiota Digest” and "Microbiota Mag" to stay up to date on the latest news about microbiota.

    * Mandatory Fields

    BMI 20-35

    • Our publications
      • News
      • Microbiota Mag
      • Thematic pages
      • Experts' point of view
      • Thematic folders
      • Overviews - Microbiota Magazine
    • About the Institute
      • Partnerships
      • Press room
      • International Microbiota Observatory
    • Congresses
      • Congress calendar
      • Congress reviews
    • Continuing Medical Education
      • Accrediting courses
      • Xpeer App
    • Useful documents
      • Infographics
      • IBS Diagnosis Check List
      • Patients Stories
      About the Institute

      Join the microbiota community

      • Facebook
      • Twitter
      • LinkedIn
      • YouTube

    Lay public section

    Find here your dedicated section

    Discover

    Gastroenterology
    Gynecology
    Pediatrics
    Dermatology

    Lay public section

    Find here your dedicated section

    Join the microbiota community

    • Facebook
    • Twitter
    • LinkedIn
    • YouTube

    © 2022 Biocodex. All rights reserved.

    • Cookies Policy
    • Data protection policy
    • GTU
    • Sitemap
    • Cookies settings
    Biocodex logo